Literature DB >> 7196283

DNA cross-linking and cytotoxicity induced by cis-diamminedichloroplatinum(II) in human normal and tumor cell lines.

G Laurent, L C Erickson, N A Sharkey, K W Kohn.   

Abstract

We have studied the cytotoxicity and DNA cross-linking induced by cis-diamminedichloroplatinum(II) (cis-Pt) in a normal, a simian virus 40-transformed, and eight tumor cell lines of human origin. These cell strains were chosen on the basis of their Mer phenotype, i.e., their ability to repair DNA containing 6O-alkylated guanine. The cytotoxicity was assayed by measuring the inhibition of cell proliferation after a two-hr treatment of the cell cultures with cis-Pt concentrations ranging from 1 to 50 microM. DNA-protein cross-links and DNA interstrand cross-links were measured by DNA alkaline elution after a two-hr treatment with 10 or 20 microM cis-Pt. The different cell lines differed in sensitivity to cis-Pt. The drug concentration required to produce the same inhibition of growth varied over a 10-fold range. Cell sensitivity correlated with DNA interstrand cross-linking (r = 0.83; p less than 0.01) better than with DNA-protein cross-linking (r = 0.75; p less than 0.05). There was no correlation between cell sensitivity or DNA interstrand cross-linking and the Mer phenotype. The lack of relationship between the extent of DNA interstrand cross-linking by cis-Pt and the Mer phenotype suggests that this repair mechanism does not remove from DNA cis-Pt monoadducts that have the potential to form interstrand cross-links.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7196283

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Discrepancy between cytotoxicity and DNA interstrand crosslinking of carboplatin and cisplatin in vivo.

Authors:  W DeNeve; F Valeriote; E Tapazoglou; C Everett; A Khatana; T Corbett
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

2.  Intracellular DNA damage produced by a series of diacridines.

Authors:  I A Roos; L P Wakelin; S J Henry
Journal:  Biochem J       Date:  1985-02-15       Impact factor: 3.857

Review 3.  Antitumor activity of platinum complexes.

Authors:  J Drobník
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 4.  Resistance to cisplatin and analogues: mechanisms and potential clinical implications.

Authors:  A de Graeff; R J Slebos; S Rodenhuis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Cisplatin with high-dose infusions of hydroxyurea to inhibit DNA repair. A phase II study in non-small-cell lung cancer.

Authors:  B M Cantwell; D Veale; C Rivett; S Ghani; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Association of cytokeratin p39 with DNA in intact Novikoff hepatoma cells.

Authors:  W S Ward; W N Schmidt; C A Schmidt; L S Hnilica
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

7.  Relationship between expression of a major apurinic/apyrimidinic endonuclease (APEX nuclease) and susceptibility to genotoxic agents in human glioma cell lines.

Authors:  Y Ono; K Matsumoto; T Furuta; T Ohmoto; K Akiyama; S Seki
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

8.  DNA interstrand cross-linking and cytotoxicity induced by chloroethylnitrosoureas and cisplatin in human glioma cell lines which vary in cellular concentration of O6-alkylguanine-DNA alkyltransferase.

Authors:  J Beith; J Hartley; J Darling; R Souhami
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Nuclear Factor-kappa B as a Resistance Factor to Platinum-Based Antineoplasic Drugs.

Authors:  Vilma Maldonado Lagunas; Jorge Meléndez-Zajgla
Journal:  Met Based Drugs       Date:  2008

10.  O6-alkylguanine-DNA-alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines.

Authors:  M C Walker; J R Masters; G P Margison
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.